Literature DB >> 11994534

Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions.

Zsolt Szabo1, Una D McCann, Alan A Wilson, Ursula Scheffel, Taofeek Owonikoko, William B Mathews, Hayden T Ravert, John Hilton, Robert F Dannals, George A Ricaurte.   

Abstract

UNLABELLED: There has been considerable interest in the development of a PET radioligand selective for the serotonin (5-hydroxytryptamine [5-HT]) transporter (SERT) that can be used to image 5-HT neurons in the living human brain. The most widely used SERT radiotracer to date, trans-1,2,3,5,6,10-beta-hexahydro-6-[4-(methylthio)phenyl[pyrrolo-[2,1-a]isoquinoline ((+)-(11)C-McN5652), has been successful in this regard but may have some limitations. Recently, another promising SERT radiotracer, 3-(11)C-amino-4-(2-dimethylaminomethylphenylsulfanyl)benzonitrile ((11)C-DASB), has been described. The purpose of this study was to compare and contrast (+)-(11)C-McN5652 and (11)C-DASB under various experimental conditions.
METHODS: Radioligand comparisons were performed in a control baboon, a baboon with reduced SERT density ((+/-)-3,4-methylenedioxymethamphetamine [MDMA] lesion), and a baboon with reduced SERT availability (paroxetine pretreatment). Under each of these experimental conditions, repeated (triplicate) PET studies were performed with each ligand.
RESULTS: Both radiotracers bound preferentially in brain regions known to contain high SERT density. For both ligands, there was a high correlation between the amount of regional brain ligand binding and the known regional brain concentration of SERT. Binding of both ligands was decreased after MDMA neurotoxicity (reduced SERT density), and (+)-(11)C-McN5652 and (11)C-DASB were comparably effective in detecting reduced SERT density after MDMA-induced 5-HT neurotoxicity. Pretreatment with paroxetine dramatically altered the metabolism and kinetics of both tracers and appeared to displace both ligands primarily from regions with high SERT density. Compared with (+)-(11)C-McN5652, (11)C-DASB had higher brain activity and a faster washout rate and provided greater contrast between subcortical and cortical brain regions.
CONCLUSION: (11)C-DASB and (+)-(11)C-McN5652 are suitable as PET ligands of the SERT and for detecting MDMA-induced 5-HT neurotoxicity. (11)C-DASB may offer some advantages. Additional studies are needed to further characterize the properties and capabilities of both ligands in health and disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994534      PMCID: PMC2078607     

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  32 in total

1.  In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652.

Authors:  R V Parsey; L S Kegeles; D R Hwang; N Simpson; A Abi-Dargham; O Mawlawi; M Slifstein; R L Van Heertum; J J Mann; M Laruelle
Journal:  J Nucl Med       Date:  2000-09       Impact factor: 10.057

2.  In vivo detection of short- and long-term MDMA neurotoxicity--a positron emission tomography study in the living baboon brain.

Authors:  U Scheffel; Z Szabo; W B Mathews; P A Finley; R F Dannals; H T Ravert; K Szabo; J Yuan; G A Ricaurte
Journal:  Synapse       Date:  1998-06       Impact factor: 2.562

3.  Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites.

Authors:  M Laruelle; M A Vanisberg; J M Maloteaux
Journal:  Biol Psychiatry       Date:  1988-07       Impact factor: 13.382

4.  Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study.

Authors:  J H Meyer; A A Wilson; N Ginovart; V Goulding; D Hussey; K Hood; S Houle
Journal:  Am J Psychiatry       Date:  2001-11       Impact factor: 18.112

5.  Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery.

Authors:  G Hatzidimitriou; U D McCann; G A Ricaurte
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

6.  3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys.

Authors:  T R Insel; G Battaglia; J N Johannessen; S Marra; E B De Souza
Journal:  J Pharmacol Exp Ther       Date:  1989-06       Impact factor: 4.030

7.  Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines.

Authors:  A A Wilson; N Ginovart; M Schmidt; J H Meyer; P G Threlkeld; S Houle
Journal:  J Med Chem       Date:  2000-08-10       Impact factor: 7.446

8.  Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects.

Authors:  J Logan; J S Fowler; N D Volkow; A P Wolf; S L Dewey; D J Schlyer; R R MacGregor; R Hitzemann; B Bendriem; S J Gatley
Journal:  J Cereb Blood Flow Metab       Date:  1990-09       Impact factor: 6.200

Review 9.  Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy').

Authors:  G A Ricaurte; U D McCann; Z Szabo; U Scheffel
Journal:  Toxicol Lett       Date:  2000-03-15       Impact factor: 4.372

10.  Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings.

Authors:  U D McCann; Z Szabo; U Scheffel; R F Dannals; G A Ricaurte
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

View more
  28 in total

1.  The 5-HT(2A) receptor and serotonin transporter in Asperger's disorder: A PET study with [¹¹C]MDL 100907 and [¹¹C]DASB.

Authors:  Ragy R Girgis; Mark Slifstein; Xiaoyan Xu; W Gordon Frankle; Evdokia Anagnostou; Stacey Wasserman; Lauren Pepa; Alexander Kolevzon; Anissa Abi-Dargham; Marc Laruelle; Eric Hollander
Journal:  Psychiatry Res       Date:  2011-11-12       Impact factor: 3.222

2.  Metabolism and disposition of 3,4-methylenedioxymethamphetamine ("ecstasy") in baboons after oral administration: comparison with humans reveals marked differences.

Authors:  Melanie Mueller; Amy K Goodwin; Nancy A Ator; Una D McCann; George A Ricaurte
Journal:  J Pharmacol Exp Ther       Date:  2011-04-14       Impact factor: 4.030

3.  Synthesis, radiosynthesis, and biological evaluation of fluorine-18-labeled 2beta-carbo(fluoroalkoxy)-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.

Authors:  Jeffrey S Stehouwer; Nachwa Jarkas; Fanxing Zeng; Ronald J Voll; Larry Williams; Vernon M Camp; Eugene J Malveaux; John R Votaw; Leonard Howell; Michael J Owens; Mark M Goodman
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

4.  Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance.

Authors:  Una D McCann; Zsolt Szabo; Melin Vranesic; Michael Palermo; William B Mathews; Hayden T Ravert; Robert F Dannals; George A Ricaurte
Journal:  Psychopharmacology (Berl)       Date:  2008-07-27       Impact factor: 4.530

Review 5.  The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.

Authors:  Yosta Vegting; Liesbeth Reneman; Jan Booij
Journal:  Psychopharmacology (Berl)       Date:  2016-08-28       Impact factor: 4.530

6.  Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users.

Authors:  Ralph Buchert; Rainer Thomasius; Kay Petersen; Florian Wilke; Jost Obrocki; Bruno Nebeling; Lutz Wartberg; Pavlina Zapletalova; Malte Clausen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-17       Impact factor: 9.236

Review 7.  Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans.

Authors:  A R Green; M V King; S E Shortall; K C F Fone
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

8.  Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET.

Authors:  Dean F Wong; James R Brasić; Harvey S Singer; David J Schretlen; Hiroto Kuwabara; Yun Zhou; Ayon Nandi; Marika A Maris; Mohab Alexander; Weiguo Ye; Olivier Rousset; Anil Kumar; Zsolt Szabo; Albert Gjedde; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2007-11-07       Impact factor: 7.853

9.  Positron emission tomography quantification of serotonin transporter in suicide attempters with major depressive disorder.

Authors:  Jeffrey M Miller; Natalie Hesselgrave; R Todd Ogden; Gregory M Sullivan; Maria A Oquendo; J John Mann; Ramin V Parsey
Journal:  Biol Psychiatry       Date:  2013-03-01       Impact factor: 13.382

10.  Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa.

Authors:  Ursula F Bailer; Guido K Frank; Julie C Price; Carolyn C Meltzer; Carl Becker; Chester A Mathis; Angela Wagner; Nicole C Barbarich-Marsteller; Cinnamon S Bloss; Karen Putnam; Nicholas J Schork; Anthony Gamst; Walter H Kaye
Journal:  Psychiatry Res       Date:  2012-11-13       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.